Cargando…

Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing

Automation of pharmaceutical safety case processing represents a significant opportunity to affect the strongest cost driver for a company's overall pharmacovigilance budget. A pilot was undertaken to test the feasibility of using artificial intelligence and robotic process automation to automa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmider, Juergen, Kumar, Krishan, LaForest, Chantal, Swankoski, Brian, Naim, Karen, Caubel, Patrick M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590385/ https://www.ncbi.nlm.nih.gov/pubmed/30303528 http://dx.doi.org/10.1002/cpt.1255

Ejemplares similares

Artificial intelligence in pharmacovigilance: Practical utility
por: Murali, Kotni, et al.
Publicado: (2019)

“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?
por: Ball, Robert, et al.
Publicado: (2022)

Response to "Pharmacovigilance 2030: Invited Commentary for the January 2020 ‘Futures’ Edition"
por: Hauben, Manfred, et al.
Publicado: (2020)

Artificial Intelligence-Based Pharmacovigilance in the Setting of Limited Resources
por: Liang, Likeng, et al.
Publicado: (2022)

Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance
por: Kassekert, Raymond, et al.
Publicado: (2022)

Effects of the COVID-19 Pandemic on Pharmacovigilance Strategy, Systems, and Processes of Large, Medium, and Small Companies: An Industry Survey
por: Beninger, Paul, et al.
Publicado: (2022)

Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data
por: Martin, Guillaume L., et al.
Publicado: (2022)

Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review
por: Kompa, Benjamin, et al.
Publicado: (2022)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis
por: Scicchitano, Francesca, et al.
Publicado: (2012)

Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
por: Giofrè, Chiara, et al.
Publicado: (2013)

Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
por: Rodríguez, Sandra, et al.
Publicado: (2020)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Correction to: Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review
por: Kompa, Benjamin, et al.
Publicado: (2023)

Innovative applications of artificial intelligence
Publicado: (1989)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
por: Li, Meng, et al.
Publicado: (2022)

The Role of Social Media for Identifying Adverse Drug Events Data in Pharmacovigilance: Protocol for a Scoping Review
por: Golder, Su, et al.
Publicado: (2023)

ADE Eval: An Evaluation of Text Processing Systems for Adverse Event Extraction from Drug Labels for Pharmacovigilance
por: Bayer, Samuel, et al.
Publicado: (2020)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance
por: Vilar, Santiago, et al.
Publicado: (2015)

Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems
por: Shrestha, Sunil, et al.
Publicado: (2021)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
por: Zhao, Dehua, et al.
Publicado: (2023)

The knowledge, attitude and behaviours of nurses about pharmacovigilance, adverse drug reaction and adverse event reporting in a state hospital
por: Vural, Fisun, et al.
Publicado: (2015)

Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2021)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India
por: Prakash, Jai, et al.
Publicado: (2021)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication
por: Choi, Yeo Jin, et al.
Publicado: (2023)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

A Pharmacovigilance Study of Drug-Induced Glaucoma Utilizing the Japanese Adverse Event Reporting System
por: Kozaru, Mariko, et al.
Publicado: (2023)

Intelligent Telehealth in Pharmacovigilance: A Future Perspective
por: Edrees, Heba, et al.
Publicado: (2022)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_235thjv9ndmg3ecse8jeuvbrfk